Placebo News and Research

RSS

Study demonstrates that stress hormone cortisol can reduce heroin cravings

Every addiction is characterized by a strong desire for a certain addictive substance, be it nicotine, alcohol or other drug. Researchers at the University of Basel in Switzerland recently conducted a study on heroin addiction and demonstrated that the stress hormone cortisol can reduce addictive cravings.

29 Jul 2015

CU-Boulder study reveals how and when placebo effect works

You don't think you're hungry, then a friend mentions how hungry he is or you smell some freshly baked pizza and whoaaa, you suddenly feel really hungry. Or, you've had surgery and need a bit of morphine for pain. As soon as you hit that button you feel relief even though the medicine hasn't even hit your bloodstream.

25 Jul 2015

FDA approves Praluent (alirocumab) Injection for treatment of patients with high LDL cholesterol

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration approved Praluent (alirocumab) Injection, the first FDA-approved treatment in a new class of drugs known as PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors.

25 Jul 2015

Eradicating H. pylori bacterium with short course of therapy may help prevent gastric cancer

A new review published in the Cochrane Library, indicates that eradicating Helicobacter pylori bacterium-- the main cause of stomach ulcers - with a short course of therapy comprising two commonly used medicines may help to reduce the risk of gastric cancer. Stomach, or gastric, cancer is the third most common cause of death from cancer worldwide, and people who are infected with the Helicobacter pylori bacterium are more likely to develop the disease.

23 Jul 2015

Phase 3 SUMIT study: Selumetinib fails to meet primary endpoint in patients with metastatic uveal melanoma

AstraZeneca today announced that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival. This combination therapy showed an adverse event profile generally consistent with current knowledge of the safety profiles of dacarbazine and selumetinib.

23 Jul 2015

InnaVirVax presents positive results of IVVAC-3S/P1 study at International AIDS Society Conference

InnaVirVax, a biopharmaceutical company specialized in research and development of therapeutic and diagnostic solutions for major infectious and chronic diseases, today announced the overall results of its Phase I/IIa clinical study of its VAC-3S immunotherapy, which is currently in development.

22 Jul 2015

Elderberry supplement can provide protection from cold, flu-like symptoms following long-haul flights

The negative health effects of international air travel are well documented but now it seems that the common elderberry can provide some relief.

22 Jul 2015

Tamsulosin works better on large kidney stones

Tamsulosin works no better than placebo on small kidney stones, but does improve passage of more large kidney stones than placebo does. The results of this large clinical trial evaluating tamsulosin versus placebo were published online Friday in Annals of Emergency Medicine ("Distal Ureteric Stones and Tamsulosin: A Double-Blind, Placebo-Controlled, Randomized, Multi-Center Trial (The DUST Trial)").

22 Jul 2015

Young, single South African women adhere well to daily PrEP regimen to prevent HIV infection

A clinical study funded by the National Institutes of Health has found that young, single black women in South Africa adhered to a daily pill regimen to prevent HIV infection--an HIV prevention strategy known as pre-exposure prophylaxis, or PrEP. This finding is the first strong indication that this population at substantial HIV risk could accept and reliably adhere to daily PrEP dosing.

22 Jul 2015

RepliCel obtains two important approvals to conduct RCS-01 phase 1 human clinical trial

RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced it has received two important approvals required to conduct its RCS-01 phase 1 human clinical trial.

21 Jul 2015

MGB Biopharma begins MGB-BP-3 Phase I clinical trial for treatment of Clostridium difficile infections

MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, to address the major global problem of antibiotic resistance today announces that the first group of healthy male volunteers have been dosed in a Phase I clinical trial assessing the safety and tolerability of an oral formulation of MGB-BP-3, for use in the treatment of Clostridium difficile infections.

21 Jul 2015

Alefacept drug offers clinical benefit to certain individuals with new-onset type 1 diabetes

Individuals with new-onset type 1 diabetes who took two courses of alefacept (Amevive®, Astellas Pharma Inc.) soon after diagnosis show preserved beta cell function after two years compared to those who received a placebo.

21 Jul 2015

Phase II open-label study demonstrates that high-risk populations adhere well to daily regimen of PrEP

Results from HPTN 067, a Phase II, randomized, open-label study, demonstrate most study participants had higher coverage of sex events and better adherence when they were assigned to the daily dosing arm, investigators from the HIV Prevention Trials Network (HPTN) reported today at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver, Canada.

21 Jul 2015

Allergan announces U.S. availability of SAPHRIS 2.5 mg tablets for children with bipolar I disorder

Allergan plc today announced that SAPHRIS (asenapine) 2.5 mg sublingual (placed under the tongue) black-cherry flavored tablets are available in pharmacies throughout the U.S. In March 2015, the U.S. Food and Drug Administration approved SAPHRIS for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients (ages 10 – 17).

17 Jul 2015

C2N-8E12 (ABBV-8E12) gets orphan drug designation from FDA for PSP treatment

C2N Diagnostics and AbbVie today announced that the U.S. Food and Drug Administration has granted their investigational recombinant humanized anti-tau antibody, C2N-8E12 (ABBV-8E12), an orphan drug designation for the treatment of progressive supranuclear palsy (PSP).

17 Jul 2015

Transcranial magnetic stimulation holds promise for tinnitus patients

In the largest U.S. clinical trial of its kind funded by the Veterans Affairs Rehabilitation Research and Development Service, researchers at the VA Portland Medical Center and Oregon Health & Science University found that transcranial magnetic stimulation significantly improved tinnitus symptoms for more than half of study participants.

17 Jul 2015

Loss of dietary diversity contributes to rise in obesity, Type 2 diabetes and other diseases

A loss of dietary diversity during the past 50 years could be a contributing factor to the rise in obesity, Type 2 diabetes, gastrointestinal problems and other diseases, according to a lecture by Mark Heiman, vice president and chief scientific officer at MicroBiome Therapeutics, at IFT15: Where Science Feeds Innovation hosted by the Institute of Food Technologists in Chicago.

16 Jul 2015

Oral PAH treatments stave off clinical decline

Oral treatments for pulmonary arterial hypertension reduce patients’ risk of clinical worsening but have little effect on survival, say the authors of a meta-analysis.

15 Jul 2015

Oxford University performs second phase of experimental Ebola vaccine trial

Oxford University doctors and scientists are performing the second phase of clinical studies of an experimental Ebola vaccine regimen. The study is part of the EBOVAC2 project, a collaborative programme involving the University of Oxford, French Institute of Health and Medical Research as project coordinator, London School of Hygiene & Tropical Medicine, Le Centre Muraz, Inserm Transfert and the Janssen Pharmaceutical Companies of Johnson & Johnson.

15 Jul 2015

Acupuncture can be more effective in treatment of dermatologic conditions

Medical evidence supports the potential for acupuncture to be significantly more effective in the treatment of dermatologic conditions such as dermatitis, pruritus, and urticaria than alternative treatment options, "placebo acupuncture," or no treatment, according to a review of the medical literature published in the Journal of Alternative and Complementary Medicine, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.

15 Jul 2015

Placebo News and Research

Study demonstrates that stress hormone cortisol can reduce heroin cravings

CU-Boulder study reveals how and when placebo effect works

FDA approves Praluent (alirocumab) Injection for treatment of patients with high LDL cholesterol

Eradicating H. pylori bacterium with short course of therapy may help prevent gastric cancer

Phase 3 SUMIT study: Selumetinib fails to meet primary endpoint in patients with metastatic uveal melanoma

InnaVirVax presents positive results of IVVAC-3S/P1 study at International AIDS Society Conference

Elderberry supplement can provide protection from cold, flu-like symptoms following long-haul flights

Tamsulosin works better on large kidney stones

Young, single South African women adhere well to daily PrEP regimen to prevent HIV infection

RepliCel obtains two important approvals to conduct RCS-01 phase 1 human clinical trial

MGB Biopharma begins MGB-BP-3 Phase I clinical trial for treatment of Clostridium difficile infections

Alefacept drug offers clinical benefit to certain individuals with new-onset type 1 diabetes

Phase II open-label study demonstrates that high-risk populations adhere well to daily regimen of PrEP

Allergan announces U.S. availability of SAPHRIS 2.5 mg tablets for children with bipolar I disorder

C2N-8E12 (ABBV-8E12) gets orphan drug designation from FDA for PSP treatment

Transcranial magnetic stimulation holds promise for tinnitus patients

Loss of dietary diversity contributes to rise in obesity, Type 2 diabetes and other diseases

Oral PAH treatments stave off clinical decline

Oxford University performs second phase of experimental Ebola vaccine trial

Acupuncture can be more effective in treatment of dermatologic conditions

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News